Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 570 clinical trials
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

years of age with multiple myeloma for autologous transplantation. Study Duration-Screening-up to 30-day. Intervention and CD34+cells apheresis up-to 8 day. A follow up for 30 days (+7 days) post last

  • 23 Jan, 2022
  • 1 location
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with daratumumab

proteasome inhibitor
  • 16 Jan, 2022
  • 9 locations
Myeloma-Developing Regimens Using Genomics (MyDRUG)

. The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell

  • 16 Sep, 2021
  • 14 locations
Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

CART therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see if this helps people with high risk multiple myeloma after

  • 29 May, 2021
  • 1 location
Study of SubQ Dara With Dose-Attenuated Bortezomib Lenalidomide Dexamethasone in Elderly NDMM

This is a single center, open-label, phase 2 study in elderly (age 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous

  • 10 Dec, 2021
  • 1 location
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors Immunomodulators and Anti-CD38 Antibody.

To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti

  • 26 Jan, 2021
  • 5 locations
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

patients with multiple myeloma who have achieved at least partial response (PR) or better after receiving a bortezomib- and lenalidomide-containing combination front-line therapy.

  • 26 Jan, 2021
  • 1 location
Treatment of Relapsed/Refractory Multiple Myeloma With t 11;14 Translocation Using BGB-11417 With Dexamethasone; Also Using BGB-11417 in Combination With Dexamethasone and Carfilzomib.

Study consists of two parts, a part 1 dose escalation and a part 2 (cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts)

  • 08 Oct, 2021
  • 2 locations
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged 70 Years) With NDMM

As optimal tolerance is the key for developing new treatments for the very elderly population, the aim of the study is to compare the efficacy and tolerance of isatuximab in combination with lenalidomide+dexamethasone (Rd) versus Rd only in very elderly patients aged 70 years or older. ln sum, a clear …

  • 08 Nov, 2021
  • 10 locations
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction Follow by Dara Consolidation

The best induction protocol to eligible multiple myeloma patients was not established. Combination of three drugs demonstrated better outcomes than two drugs combo. Nevertheless, until now four

  • 22 Jan, 2021
  • 1 location